The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...

Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 - ...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with ...

Patients with obesity sometimes have leptin resistance, and the "full" feeling does not get through to the brain. The new ...

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) today announced its full-year results for the period ending ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts ...

Equity-Insider.com News Commentary -- Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing ...

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...

Little Luna Ann Forsyth has had to have two surgeries and could face another following the attack in Stockingford three years ...

Thank you, and welcome to Curis' Fourth Quarter 2025 Business Update Call. Before we begin, I'd like to encourage ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...

Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim ...